findmyKOL
Clinical trialNCT06920043RecruitingPhase 2Interventional

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

SponsorGlaxoSmithKlineEnrollment42Metabolic Dysfunction-Associated SteatohepatitisNon-alcoholic Fatty Liver Disease
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Gsk Investigational Site

    Chandler, Arizona, United States

    Anita Kohli
    Recruiting
  • Gsk Investigational Site

    Mesa, Arizona, United States

    Ann Moore
    Recruiting
  • Gsk Investigational Site

    Tucson, Arizona, United States

    Aimee Bachelier
    Recruiting
  • Gsk Investigational Site

    Fresno, California, United States

    Muhammad Sheikh
    Recruiting
  • Gsk Investigational Site

    Lancaster, California, United States

    Jatinder Pruthi
    Recruiting
  • Gsk Investigational Site

    Pasadena, California, United States

    Edward Mena
    Recruiting
  • Gsk Investigational Site

    Rialto, California, United States

    Zeid Kayali
    Recruiting
  • Gsk Investigational Site

    Santa Maria, California, United States

    Keval Shah
    Recruiting
  • Gsk Investigational Site

    Miami, Florida, United States

    Lazaro M Garcia
    Recruiting
  • Gsk Investigational Site

    Viera, Florida, United States

    Rosemary Laird
    Recruiting
  • Gsk Investigational Site

    Marietta, Georgia, United States

    Aasim Sheikh
    Recruiting
  • Gsk Investigational Site

    Baltimore, Maryland, United States

    Paul Thuluvath
    Recruiting
  • Gsk Investigational Site

    Kansas City, Missouri, United States

    Bradley Freilich
    Recruiting
  • Gsk Investigational Site

    New York, New York, United States

    Frances Lee
    Recruiting
  • Gsk Investigational Site

    Fayetteville, North Carolina, United States

    John Poulos
    Recruiting
  • Gsk Investigational Site

    Wilson, North Carolina, United States

    Mitchell Mahmoud
    Recruiting
  • Gsk Investigational Site

    Austin, Texas, United States

    Rohit Puskoor
    Recruiting
  • Gsk Investigational Site

    Austin, Texas, United States

    Carmen Landaverde
    Recruiting
  • Gsk Investigational Site

    Austin, Texas, United States

    Nomita Kim
    Recruiting
  • Gsk Investigational Site

    Dallas, Texas, United States

    Recruiting
  • Gsk Investigational Site

    Georgetown, Texas, United States

    Nirupama Jerome
    Recruiting
  • Gsk Investigational Site

    Houston, Texas, United States

    Prasun Jalal
    Recruiting
  • Gsk Investigational Site

    Houston, Texas, United States

    Joseph Galati
    Recruiting
  • Gsk Investigational Site

    Houston, Texas, United States

    David Huang
    Recruiting
  • Gsk Investigational Site

    Pasadena, Texas, United States

    Rukan Daccak
    Recruiting
  • Gsk Investigational Site

    Pearland, Texas, United States

    Jignesh Shah
    Recruiting
  • Gsk Investigational Site

    San Antonio, Texas, United States

    Recruiting
  • Gsk Investigational Site

    San Antonio, Texas, United States

    Daniel Santillano
    Recruiting
  • Gsk Investigational Site

    Waco, Texas, United States

    Gregg Lucksinger
    Recruiting
  • Gsk Investigational Site

    Richmond, Virginia, United States

    Michael Fuchs
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Apr 2025
Primary completion
10 Jul 2028
Completion
10 Jul 2028
Last update posted
8 Jul 2026
Registered enrollment
42
Registry id
NCT06920043

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.